N/A N=37 Effects of Home-based Program in Improving Sitting Balance and Upper Limb Functions in Patients With Stroke
Stroke
Primary: Trunk Impairment Scale — 13.2; 13.8; 13.9; 19.0 units on a scale — p=<0.001
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=237 Palmoplantar Pustular Psoriasis Efficacy and Safety With Secukinumab
Palmoplantar Pustular Psoriasis
Primary: Percentage of Participants With ppPASI 75 Response at Week 16 (Period 1) — 17.5; 26.6; 14.1 percentage of participants — p=0.5722
Phase 2 N=81 Development of Read-outs in Healthy, Hepatitis B Virus Naive Adults Vaccinated With the Hepatitis B Surface Antigen (HBsAg) in Combination With a GlaxoSmithKline (GSK) Biologicals' Adjuvant System
Hepatitis B
Primary: Concentrations of Cytokines and Chemokines - Step 1 — 6000; 6250; 14; 14 pg/mL
Phase 1 N=90 BI 860585 Dose Escalation Single Agent and in Combination With Exemestane or With Paclitaxel in Patients With Various Advanced and/or Metastatic Solid Tumors
Neoplasms
Primary: The Number of Patients With Dose-Limiting Toxicities (DLTs) in the First Course of Each Treatment Arm — 4; 4; 2 Participants
Phase 3 N=2,712 Repeat Ivermectin Mass Drug Administrations for Control of Malaria: a Pilot Safety and Efficacy Study
Malaria · Lymphatic Filariasis
Primary: Incidence of Clinical Malaria Episodes — 2.49; 2.00 episodes
Phase 3 N=1,672 Efficacy, Safety, and Tolerability Study of Oral Ubrogepant in the Acute Treatment of Migraine
Migraine, With or Without Aura
Primary: Percentage of Participants With Pain Freedom at 2 Hours After Initial Dose — 11.8; 19.2; 21.2 percentage of participants — p=0.0023
N/A N=84 Guanfacine for PONV and Pain After Sinus Surgery
Postoperative Nausea and Vomiting · Pain, Postoperative
Primary: Comparison of PONV Score of Assessments Done at 15 Minutes After Arrival in PACU Using 11-point Nausea Scale (nVRS) — 35; 33; 1; 2 Participants
Phase 3 N=4,005 A Trial to Evaluate Immunogenicity and Safety of Three Consecutive Production Lots of IMVAMUNE® (MVA-BN®) Smallpox Vaccine in Healthy, Vaccinia-naïve Subjects
Smallpox
Primary: PRNT GMT — 110.7; 100.5; 117.2; 1.0 Titer
N/A N=1,600 Social Media And Risk-reduction Training for Infant Care Practices (SMART)
Risk Reduction
Primary: Adherence With Recommended Supine Sleep Position — 230; 294; 294; 243 Participants — p=0.03
Phase 2 N=9 The Probiotic Study: Using Bacteria to Calm Your Mind
Anxiety · Abdominal Pain
Primary: Change in Child Abdominal Pain Rating — 0.36 units on a scale
Phase 4 N=31 Preemie Tots: A Pilot Study to Understand the Effects of Prematurity in Toddlerhood
Preterm Birth · Child Development · Child Behavior
Primary: Child Behavior - Pervasive Developmental Disorders Screening Test-II Stage 2 — -1.0; -0.2 score on a scale — p=0.67
N/A N=199 Hummingbird TTS Ear Tube Delivery Study
Otitis Media
Primary: Percentage of Ears in Which an Ear Tube Was Successfully Delivered Across the Tympanic Membrane — 393 Ears
N/A N=135 Absorb GT1 Japan PMS
Ischemic Heart Disease · Angina Pectoris · Coronary Artery Disease
Primary: Number of Participants With Acute Scaffold Thrombosis (ST) — 0; 0; 0 participants
Phase 1 N=30 TAK-438 Bismuth Drug Interaction Study
Helicobacter Pylori
Primary: Percentage of Participants Who Experience at Least One Treatment Emergent Adverse Event (TEAE) — 53.3; 66.7 percentage of participants
Phase 2 N=10 Complement Inhibition Using Eculizumab to Overcome Platelet Transfusion Refractoriness in Patients With Severe Thrombocytopenia
Thrombocytopenia · Alloimmune Platelet Refractoriness
Primary: Number of Subjects With Sustained Platelet Transfusion Responsiveness — 4 Participants